The FDA has endorsed Pfizer’s respiratory ... While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE ... with 65% opting for GSK's Arexvy. However, this September, the weekly average fell to 157,000. Price Action: PFE stock is down 0.36% at ...

The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...

The FDA has approved Pfizer’s respiratory syncytial ... for severe RSV should receive a single dose of the RSV vaccine (Arexvy [GSK], Abrysvo [Pfizer], or mResvia [Moderna]).

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

Sales of all three FDA-approved vaccines in the 2024-25 season will be scrutinised to gauge the impact of that new advice. Last year, Arexvy came out on top in the market tussle with sales of $1.6 ...

In addition to Abrysvo and Arexvy, there is a new entrant in the RSV adult market as Moderna scored FDA approval for its vaccine mRESVIA five months ago. That nod covers patients 60 and older.

GSK is also conducting clinical studies on Arexvy for expanded use in adults aged 18-49 years. Moderna MRNA secured FDA approval for its mRNA-based RSV vaccine, mResvia, this May to prevent RSV ...

Other companies also have FDA-approved RSV vaccines , including Moderna’s mResvia and GSK’s Arexvy. However, Pfizer’s Abrysvo ...